NIH Child Health Institute Schedules Routine Research Meeting
Published Date: 9/4/2025
Notice
Summary
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a public meeting on December 4, 2026, to share updates on their research and organization. Part of the meeting will be private to review grant applications and staff performance, keeping personal details confidential. This meeting affects researchers and grant applicants and helps guide important funding and research decisions.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Open Session Is Videocast Publicly
You can watch the meeting's open session via the NIH Videocast website (http://videocast.nih.gov/). The open session is scheduled for December 4, 2026, from 10:00 a.m. to 12:40 p.m.
Advance Notice for Accessibility Needs
If you plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, you should notify the listed contact person in advance of the meeting.
Confidential Grant Application Review
The meeting will be closed from 12:40 p.m. to 2:45 p.m. on December 4, 2026 to review and evaluate individual grant applications and personnel qualifications; personal information will be kept confidential under 5 U.S.C. 552b(c)(4) and (c)(6).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-16940, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in October 2025 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which science projects get funding. Researchers applying for grants and NIH staff are the main players, with no changes to timing or money announced.
Next: 2025-16944, Pesticide Registration Review; Pesticide Dockets Opened for Review and Comment; Notice of Availability
The EPA is inviting everyone to check out and comment on their plans for reviewing two chemicals: ethaboxam and urea sulfate. This is a chance for the public to help shape how these pesticides are managed to keep people and the environment safe. Don’t miss your chance to weigh in before the review moves forward!